- Calgene Inc., of Davis, Calif., said Thursday it filed a request withHealth Canada seeking permission to sell Flavr Savr tomatoes in thatcountry. The review time for the procedure is 90 days. The tomatoeswere granted U.S. clearance by the FDA on May 18, and went on salein limited markets a few days later. Calgene said it is scaling upproduction for a major product roll-out this fall.- Apollo Genetics Inc., of Cambridge, Mass., and Endocon Inc., ofSouth Walpole, Mass., have formed a joint venture to focus onsustained delivery of estrogen compounds for the treatment of age-related neurological diseases. The collaboration, called AGE, will becentered on work for a subcutaneous release of estrogen compoundsfor Alzheimer's disease.- Nasdaq told Biodynamics International Inc. (NASDAQ:BDYNC), ofTampa, that its trading symbol for common stock will revert to BDYN,effective today. Biodynamics has been trading under an exemptionfrom Nasdaq and Surplus requirement. The removal of the "C" followsthe filing of a Form 8-K with the Securities and Exchange Commissionwhich included the pro forma effect of the debt to equity exchangeannounced by the company in May.- Immunomedics Inc., of Morris Plains, N.J., received $156,000 fortwo Small Business Innovation Research grants from the NationalCancer Institute to develop antibody drug conjugates and radioisotope-antibody conjugates.- Rhone-Poulenc Rorer acquired European marketing rights to the anti-cancer compound, irinotecan, also called CPT-11. The license wasacquired from Yakult Honsha Ltd. in Tokyo. Under the agreement,Rhone-Poulenc Rorer will develop the compound using raw materialssupplied by Yakult.- Celgene Corp., of Warren, N.J., signed an agreement with SybronChemicals Inc., for Celgene to license its biocatalysis technology forthe removal of hazardous waste from manufacturing and process wastestreams to Sybron. Celgene will receive royalty payments based oncommercial sales.- Quadra Logic Technologies Inc., of Vancouver, and Ciba-Geigy Ltd.,of Basel, Switzerland, are collaborating to develop light-activateddrugs for use in Photodynamic Therapy as a potential treatment ofcancer and psoriasis.
(c) 1997 American Health Consultants. All rights reserved.